翻訳と辞書 |
Biotie Therapies : ウィキペディア英語版 | Biotie Therapies
Biotie Therapies is a Finnish biotechnology and pharmaceutics company. The company's research and development is focused on drugs for neurodegenerative and psychiatric disorders like Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence and post traumatic stress disorder, and inflammatory and fibrotic liver disease. The company's headquarters is in Turku, Western Finland, and it is listed on NASDAQ OMX Helsinki. == Overview == Biotie Therapies was formed in the merger of Biotie Therapies Corp. (incorporated in 1998), Oy Contral Pharma Ltd and Carbion Inc in the year 2002. In 2008, Biotie Therapies acquired the German pharmaceutical discovery and development company elbion GmbH in Radebeul. In 2010 Biotie Therapies all preclinical assets were transferred into a new company, biocrea GmbH, in which Biotie become a minority shareholder. In 2011, Biotie acquired a pharmaceutical company Synosia. The company has partnering agreements with H. Lundbeck A/S and UCB.〔(Biotie Therapies Oyj Company Description ) Business Week〕
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Biotie Therapies」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|